Compare XPOF & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | AMRN |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.4M | 336.1M |
| IPO Year | 2021 | 1998 |
| Metric | XPOF | AMRN |
|---|---|---|
| Price | $6.79 | $16.01 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 6 | 1 |
| Target Price | $8.13 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 481.1K | 85.6K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.24 | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | $11,092,000.00 | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.63 | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $3.83 | $12.96 |
| 52 Week High | $11.14 | $20.90 |
| Indicator | XPOF | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 68.54 |
| Support Level | $6.64 | $13.58 |
| Resistance Level | $7.08 | $17.00 |
| Average True Range (ATR) | 0.34 | 0.66 |
| MACD | 0.16 | 0.17 |
| Stochastic Oscillator | 88.33 | 89.83 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.